Piper Jaffray Downgrades Novavax (NVAX) to Neutral
- Wall St. rises amid robust earnings, GDP data
- FBI to review more emails related to Clinton's private email use: letter
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Piper Jaffray downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $1.00 (from $14.00).
Shares of Novavax closed at $8.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Partners Downgrades McKesson (MCK) to Market Perform
- Imperial Capital Downgrades Brinks Co. (BCO) to In-Line
- Craig-Hallum Downgrades eHealth (EHTH) to Hold
Create E-mail Alert Related CategoriesAnalyst PT Change, Downgrades
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!